

Bringing in the Research Dollars! (BiRD)



**Presented by:
The Emory+Children's Pediatric Research Center**

The monthly BiRD announcement highlights
pediatric research funding opportunities

Contact stacy.heilman@emory.edu with questions on the funding opportunities
highlighted below or for general research grant application advice

December 2011 BiRD Contents

- ❖ NHLBI themed research for [research dissemination and implementation](#) and [ancillary studies in clinical trials](#)
- ❖ Program announcements for conducting research on [neonatal hypoglycemia](#) and towards [advancing vaccine safety](#)
- ❖ Request for proposal to participate in the [Asthma & Allergic Diseases Cooperative Research Centers](#)
- ❖ Funds available for [shared instrumentation](#) purchases
- ❖ Health care delivery/outcomes/clinical effectiveness research focused [on economical ways to improve patient outcomes](#), supporting [system modeling research](#), an [intramural seed grant](#) opportunity and a [career development research starter grant](#) opportunity
- ❖ Research funds available for [interventional approaches to address multiple chronic health conditions](#) and [towards improving medication adherence](#), both in a primary care setting
- ❖ Resources and funds for investigator-Initiated studies using drugs available from [Bristol-Myers Squibb](#) and [Pfizer](#)
- ❖ Foundation support from the [Thrasher Research Fund](#) and the Gates Foundation for research towards [achieving healthy growth for children in the developing world](#)
- ❖ Availability of intramural research seed funds specifically for the [Pediatric Research Centers](#) and supported themes, for the [general Emory faculty community](#) and for [molecular and translational imaging research](#)
- ❖ Bridge funds for [childhood cancer researchers](#)
- ❖ ACTSI sponsored [KL2](#) program announcement
- ❖ Announcement of various [educational opportunities](#) especially suited for junior faculty

GENERAL FEDERAL/COLLABORATIVE POTENTIAL

Program/Link **NHLBI Research Dissemination and Implementation Grants (R18)**
<http://grants.nih.gov/grants/guide/pa-files/PA-12-063.html>

Purpose The National Heart, Lung, and Blood Institute invites Research Dissemination and Implementation (R18) applications from institutes/organizations that propose studies which will develop and test strategies to accelerate the adoption and integration of evidence into practice. The purpose of this FOA is to support dissemination and implementation studies to 1) develop innovative dissemination and implementation approaches to translating efficacious treatments for heart, lung, and blood diseases and sleep disorders in the clinic, community, and other real-world settings; 2) test the effectiveness, sustainability, determinants, feasibility, and cost-effectiveness of these approaches in a variety of real-world settings; and 3) examine the effectiveness of interventions as they are disseminated and implemented in real-world settings to reduce risk factors for and enhance prevention and treatment of heart, lung, and blood diseases and sleep disorders.

Funds Avail Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum period is 5 years.

Deadline Standard NIH deadlines*

Remarks

- Research Dissemination and Implementation (D&I) studies involve extending or adapting generally accepted, efficacious, and/or guideline-based interventions such as behavioral techniques; educational, environmental or organizational strategies; and healthcare services such as pharmacotherapies and others, and applying them to broader real-world populations, settings, and conditions such as clinic, community, school and work environments, and other real-world settings.
- Encourages multi-PI applications

Program/Link **Ancillary Studies in Clinical Trials (R01)**
<http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-13-003.html>

Purpose Inviting research grant applications to conduct time-sensitive ancillary studies related to heart, lung, and blood diseases and sleep disorders in conjunction with ongoing clinical trials and other large clinical studies supported by NIH or non-NIH entities. The program establishes an accelerated review/award process to support the crucial time frame in which these ancillary studies must be performed. Time-sensitive ancillary studies include those that require active longitudinal data collection and thus need to begin recruiting subjects as close as possible to the start of the parent study. The ancillary study can address any research questions related to the mission of NHLBI for which the parent study can provide participants, infrastructure, and data. The parent studies most often will be a clinical trial, but also can be

an observational study or registry that can provide a sufficient cohort of well-characterized patients. Each ancillary study application must demonstrate the time-sensitive nature of the application and must explicitly address why an expedited review is essential to its feasibility.

- Funds Avail** An application may request a budget for direct costs up to \$250,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is four years.
- Deadline** May 24, 2012; September 24, 2012; January 24, 2013
- Remarks**
- Parent studies need not be funded by the NHLBI; they may be funded by other Institutes or government agencies or by private sponsors. However, the objective(s) of the ancillary study must fall within the mission of the NHLBI
 - This program will use a modified application process, expedited peer review, and modular funding

Program/Link **Studies in Neonatal Hypoglycemia (R01)**
<http://grants.nih.gov/grants/guide/pa-files/PA-11-053.html>

Purpose This funding opportunity announcement (FOA) is issued by the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) to encourage Research Project Grant (R01) applications from institutions and organizations to propose studies related to basic, applied and translational research in neonatal hypoglycemia. While much progress has been made in understanding the causes and mechanisms of altered neonatal glucose homeostasis, major gaps remain. Through this FOA, the NICHD is hoping to fill-in such knowledge gaps, which may lead to better monitoring and treatment strategies for altered neonatal glucose homeostasis.

Funds Avail Budgets for direct costs of up to \$499,999 per year and project duration of up to 5 years may be requested. For budgets with direct costs of \$500,000 or more please see PA for special instructions.

Deadline Standard NIH Due Dates*

- Remarks**
- Companion FOA's include:
 - NIH Small Research Grant (R03) award mechanism - <http://grants1.nih.gov/grants/guide/pa-files/PA-11-054.html>
 - NIH Exploratory/Developmental Research Grant (R21) mechanism - <http://grants1.nih.gov/grants/guide/pa-files/PA-11-055.html>

Program/Link **Asthma and Allergic Diseases Cooperative Research Centers (U19)**
<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-006.html>

Purpose The National Institute of Allergy and Infectious Diseases (NIAID) invites new or renewal applications from single institutions and consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (ADCRC) program. The purpose of this ADCRC Funding Opportunity Announcement (FOA) is to support basic and clinical research on the immunological basis, pathobiology, diagnosis, treatment and prevention of asthma and allergic diseases and to accelerate the application of fundamental knowledge of immune function to the investigation, prevention, and treatment of asthma and allergic diseases.

This FOA will focus on diseases with high public health impact. These include asthma, allergic rhinitis, chronic rhinosinusitis, atopic dermatitis and food allergy. In order to stress the integration and focus of the applications on human disease-related mechanisms, NIAID requires that the majority of the proposed research in each application be defined as NIH human subjects research.

Funds Avail Direct costs for each ADCRC award are expected to be approximately \$1,000,000 per year. Maximum project duration is 5 years.

Deadline April 24, 2012

Remarks

- Only one application per institution is allowed
- Applications considered to be responsive to this FOA must be composed of a minimum of three interrelated research projects structured around a central scientific theme that is clearly relevant to the pathogenesis of, and intervention strategies for asthma and allergic diseases.

Program/Link **Research to Advance Vaccine Safety (R01)**

<http://grants.nih.gov/grants/guide/pa-files/PA-12-037.html>

Purpose The purpose of this funding opportunity announcement (FOA) is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity invites studies that address scientific areas potentially relevant to vaccine safety such as 1) physiological and immunological responses to vaccines and vaccine components, 2) how genetic variations affect immune/physiological responses that may impact vaccine safety, 3) identification of risk factors and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines, 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources such as passive reporting systems, or 5) the application of genomic/molecular technologies to improve knowledge of vaccine safety.

Funds Avail Application budgets are not limited, but need to reflect actual needs of the proposed project.

Deadline Standard NIH Due Dates*

Remarks ➤ Companion RFA is R21 Exploratory/Developmental Research Grant
<http://grants.nih.gov/grants/guide/pa-files/PA-12-038.html>

Program/Link **Shared Instrumentation Grant Program (S10)**

<http://grants.nih.gov/grants/guide/pa-files/PA-12-017.html>

Purpose The NCCR Shared Instrument Grant (SIG) program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of expensive, specialized, commercially available instrumentation or an integrated system that costs at least \$100,000. The maximum award is \$600,000. Types of instruments supported include confocal and electron microscopes, biomedical imagers, mass spectrometers, DNA sequencers, biosensors, cell-sorters, X-ray diffraction systems, and NMR spectrometers among others.

For eligibility, a major user group of three or more investigators who are Program Director(s)/Principal Investigator(s) on active NIH research grants with the following activity codes, P01, R01, U01, R35, R37, DPI and DP2 must be identified. Once this eligibility requirement has been met, additional users with other types of active NIH research grants (such as but not limited to R03, R21, R55, P30, P41, P50) mechanisms can be added as major or minor users. NIH training grants and contracts are not eligible. To demonstrate the clear need for the requested instrumentation, the projects supported by NIH research grants should together require at least 75 percent with the major user group accounts for at least 35 percent -of the total usage time.

Funds Avail Applications will be accepted that request a single, commercially available instrument or integrated system which costs at least \$100,000. There is no upper limit on the cost of the instrument, but the maximum award is \$600,000.

Deadline March 21, 2012

Remarks ➤ There is no limit on the number of applications an institution may submit provided the applications are for different types of equipment.
➤ A list of appropriate equipment can be found at
http://ncrr.nih.gov/research_funding/instruments/

Program/Link **Economic Studies Ancillary to Completed or Ongoing Health Care Delivery and Financing Pilots, Demonstrations, and Other Experiments (R01)**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-11-023.html>

Purpose Supports health economics research ancillary to completed or ongoing large-scale health care delivery and financing pilots, demonstrations, and other experiments (PDEs) that are intended to reduce health care costs or cost growth while maintaining or improving patient outcomes.

Examples of the types of completed or ongoing PDEs that may be the basis for the proposed ancillary research relevant to this FOA may include, but are not limited to, the following:

- Care delivery organization innovations such as patient-centered medical homes, accountable care organizations, ambulatory intensive care services, and integrated medical and behavioral health care.
- Payment innovations such as pay-for-performance, bundled payment, voucher or “money follows the person,” gainsharing, or value-based purchasing programs.
- Innovations in the use of health information technology, including electronic health records for care coordination, especially across multiple health care organizations.

Examples of specific ancillary research topics that may be relevant to this FOA include, but are not limited to, the following:

- The pro- and anti-competitive effects, as well as the resulting effects on market prices and the efficiency of production, of joint contracting by clinically and financially integrated health care entities.
- The effects of innovative payment structures on organizational-level economic efficiency, quality of care, and patient outcomes.
- The effects of adopting meaningful use of electronic health records on the efficiency of health care delivery, and the costs and quality of care.
- The organizational factors and processes that affect health care organizations’ abilities to reduce costs and improve outcomes in response to health care value-enhancing payment and policy innovations.
- The outcome and cost effects of payment, structure, or organization innovations on subsets of patients, such those from vulnerable populations or those with multiple chronic conditions.

Funds Avail	Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum period is 5 years.
Deadline	February 8, 2012 (LOI due January 8, 2012)
Remarks	<ul style="list-style-type: none">➤ Projects involving multidisciplinary teams led by a health economist, or with the substantial involvement of a health economist, are encouraged.➤ All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for

rapid progress.

- Applications proposing to examine specific clinical interventions without a primary focus on the effects of structure, organization, or payment arrangements, e.g. efficacy or effectiveness studies of specific medications or procedures, are not responsive to this FOA and will not be reviewed.
- Companion FOA Phased Innovation Award R21/R33
<http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-11-024.html>

Policy researchers in the Rollins School of Public Health offer expertise in the economics of federal health policy reform. Please contact stacy.heilman@emory.edu if you would like to make collaborative connections to that group.

Program/Link **Advancing Health Services through System Modeling Research**

<http://nsf.gov/pubs/2012/nsf12515/nsf12515.htm>

Purpose NSF, in collaboration with the Health Information Technology (IT) Portfolio at the Agency for Healthcare Research and Quality (AHRQ), will accept and review investigator-initiated proposals that address systems modeling in health services research. The Service Enterprise Systems program in the Civil, Mechanical, and Manufacturing Innovation (CMMI) division of the Engineering Directorate will be the lead program on this interdisciplinary topic. Through this partnership, NSF and AHRQ look to foster new collaborations among health services researchers and industrial and systems engineers with a specific emphasis on the supportive role of health IT.

Funds Avail Not specified, but there is \$1 - \$2M available total for 3-6 awards

Deadline February 15, 2012

Remarks ➤ It is envisioned that successful proposals will be submitted by investigators from industrial engineering, and/or systems engineering, and/or management science fields in collaboration with health services researchers.

Program/Link **Practical Interventions to Improve Medication Adherence in Primary Care (R01)**

<http://grants.nih.gov/grants/guide/pa-files/PA-12-022.html>

Purpose Seeking applications that propose practical interventions to improve adherence to medication. This FOA will support research to test interventions with the potential to significantly improve medication adherence in patients with chronic health conditions in settings where primary health care is

delivered (including, dental and eye care settings). Applications may target medication adherence in the context of treatment for a single illness or chronic condition (e.g., hypertension) or multiple comorbid conditions (e.g., hypertension and HIV/AIDS). Studies should use the most rigorous design and methodology possible given the populations and settings in which the study is taking place. Primary outcomes of the research should include: a patient self-report of medication adherence, and at least one other non-self-report measure of medication adherence (e.g., pharmacy refill records, electronic monitoring, etc.). In addition, applications should include a health outcome or biomarker (e.g., blood pressure, viral load in HIV patients, cholesterol levels, HbA1c) that is expected to be affected by changes in the targeted adherence behavior. Researchers should address the capacity of the tested approach for wide dissemination, the sustainability of the approach once the research is concluded, and are encouraged to include measurement and costs of the intervention characteristics and contextual factors that affect implementation and adoption.

Funds Avail Application budgets are not limited, but need to reflect actual needs of the proposed project. Scope of the proposed project should determine the project period.

Deadline Standard NIH Due Dates*

Remarks

- Issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR), with participation from the National Cancer Institute ([NCI](#)), the National Eye Institute ([NEI](#)), the National Heart, Lung, and Blood Institute ([NHLBI](#)), the National Institute on Aging ([NIA](#)), the National Institute on Deafness and Other Communication Disorders ([NIDCD](#)), the National Institute of Diabetes and Digestive and Kidney Diseases ([NIDDK](#)), the National Institute of Mental Health ([NIMH](#)), the National Institute of Nursing Research ([NINR](#)), and the National Center for Complementary and Alternative Medicine ([NCCAM](#)).
- Companion FOA includes R21 Exploratory/Developmental Research Grant Award - <http://grants.nih.gov/grants/guide/pa-files/PA-12-023.html>

Program/Link Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01)
<http://grants.nih.gov/grants/guide/pa-files/PA-12-024.html>

Purpose This funding opportunity announcement (FOA) seeks Research Project Grant (R01) applications that propose to use a common conceptual model to develop behavioral interventions to modify health behaviors and improve

health outcomes in patients with comorbid chronic diseases and health conditions. Specifically, this FOA will support research in primary care that uses a multi-disease care management approach to behavioral interventions with high potential impact to improve patient-level health outcomes for individuals with three or more chronic health conditions. The proposed approach must modify behaviors using a common approach rather than administering a distinct intervention for each targeted behavior and/or condition. Diseases and health conditions can include, but are not limited to: mental health disorders (e.g., depression), diabetes, smoking, obesity, chronic pain, alcohol and substance abuse and dependence, chronic obstructive pulmonary disorder, cancer and hypertension.

Funds Avail Application budgets are not limited, but need to reflect actual needs of the proposed project. Scope of the proposed project should determine the project period. Maximum project duration is 5 years.

Deadline Standard NIH Due Dates*

- Remarks**
- Participating organizations include
 - Office of Behavioral and Social Sciences Research ([OBSSR](#))
 - National Cancer Institute ([NCI](#))
 - National Heart, Lung, and Blood Institute ([NHLBI](#))
 - National Institute on Aging ([NIA](#))
 - National Institute on Alcohol Abuse and Alcoholism ([NIAAA](#))
 - National Institute on Drug Abuse ([NIDA](#))
 - National Institute of Mental Health ([NIMH](#))
 - National Institute of Nursing Research ([NINR](#))
 - Interventions should be practical and have potential, if successful, for implementation in primary care (e.g., in terms of cost of training, staff, office space and patient burden)

PHARMACEUTICAL

The following opportunities offered by pharmaceutical companies are useful for those who wish to examine and/or perform studies on the specific drugs that they offer

Program/Link Bristol-Myers Squibb Investigator Sponsored Research
Clinical Research Investigators
http://www.bms.com/clinical_trials/investigator_sponsored_research/us_clinical_research_investigators/Pages/default.aspx
Non-Interventional Research
http://www.bms.com/clinical_trials/investigator_sponsored_research/noninterventional_research_investigators/Pages/default.aspx

Purpose The Bristol-Myers Squibb ISR application process provides a framework and allows investigators to work from a common set of criteria, requirements and

schedule of events. The process is designed to ensure scientific rigor and patient safety while supporting unique research ideas and providing insights into areas of unmet medical need. Requests for clinical research trials from all clinical and therapeutic areas are considered, but priority is given to proposals that support their medical plans in the following therapeutic areas: cardiovascular/metabolics, neuroscience, cancer, immunology and virology.

- Funds Avail** Not specified on website, but studies may be submitted for “drug-only” support as well as drug & funding support
- Deadline** January 15, 2012
- Remarks** ➤ See additional links at each url for products available in each therapeutic area and for specific application information

Program/Link **Pfizer Investigator-Initiated Research Grants**
http://www.pfizer.com/research/investigator/investigator_initiated_research.jsp

- Purpose** The mission of the Pfizer Investigator-Initiated Research (IIR) Program is to provide support for investigator-initiated research that advances medical and scientific knowledge about Pfizer products and generates promising medical interventions. This global program is open to all researchers who are interested in receiving support for conducting their own research.
- Types of Research Eligible for Support:
- Clinical studies of approved and unapproved uses, involving approved or unapproved Pfizer drugs
 - Observational studies, such as epidemiology studies and certain outcomes research studies where the primary focus is the scientific understanding of disease
 - Other types of independent research on disease states, including novel diagnostic screening tools and surveys where Pfizer has no direct commercial interest
 - In vitro or animal studies which include funding*

Pfizer accepts [Concept submissions](#) and Full submissions for Investigator-Initiated Research grant requests. If a Concept submission is of interest, a follow up request for a Full Submission will be issued. A Full submission must be received in order for a request to be considered for approval.

- Funds Avail** Not specified; Pfizer support is typically provided in the manner of funding, and/or drug (either formulated or pure compound) depending upon the type of research.
- Deadline** Continuous application opportunity
- Remarks** ➤ If you are interested in discussing your research questions or ideas please contact your Pfizer representative. If you do not know whom to contact, you may email iir@pfizer.com with your therapeutic area of interest and

they will provide you with a contact.

FOUNDATION

Program/Link **Thrasher Research Fund**

http://www.thrasherresearch.org/sites/www_thrasherresearch_org/Default.aspx?page=220

Purpose The Thrasher Research Fund remains open to a variety of pediatric medical research topics. Research projects with the potential to impact a large number of children as well as research projects that address severe problems affecting relatively few children will be considered. The fund seeks to maintain a portfolio of grants with a balance of both domestic and international research.

The fund supports clinical/translational pediatric research. Emphasis is placed on projects with potential findings that would be clinically applicable in a relatively short period of time for the prevention, diagnosis or treatment of pediatric medical problems.

Funds Avail Projects are supported for up to three years. The grant amount is based on the actual budgetary needs of the project. In 2009-2010 the median grant was \$300,000 for the total award (not annually).

Deadline February 29, 2012

Remarks To be eligible, physicians must:

- be committed to a career in academic medicine, public health, health policy or another career congruent with the program's purposes and priorities of developing physician leaders and skilled researchers;
- be highly regarded by those responsible for their clinical training;
- intend to complete the clinical requirements of their residency training by the date of entry into the program (except for surgeons); and
- be U.S. Citizens, Resident Non-Citizen Nationals or Resident Foreign Nationals.
- Both MDs and DOs are eligible to apply.

Program/Link **Bill & Melinda Gates Foundation Grand Challenges: Achieving Healthy Growth Grant Opportunity**

<http://www.grandchallenges.org/GrantOpportunities/Pages/healthygrowth.aspx>

Purpose The goal of this opportunity is to elucidate new pathways or mechanisms that will directly inform the development of interventions for the prevention of impaired growth, i.e. stunting and wasting, during the first 1,000 days following conception in the developing world. Ultimately the sponsors aim to identify simpler, less costly, and more effective interventions delivered before conception, during pregnancy, or in the first two years of life. To meet this goal, approaches should address the underlying biological mechanisms that lead to these adverse developmental outcomes focusing specifically on

either or both infection and nutrition, the two primary factors involved in altering the course of fetal and infant growth and development in the developing world.

Research efforts relevant to informing future interventions for treating or preventing growth restriction, stunting, or wasting may include the investigation of pathways or mechanisms:

- a) involved with the acquisition or metabolism of essential vitamins, minerals, fatty acids, or other nutrients;
- b) controlled by hormones or influenced by autonomic functions;
- c) induced by pathogens or immunological activity; or
- d) environmental toxins.

The Discover New Ways to Achieve Healthy Growth program will address three developmental segments or age groups:

- 1. prenatal, including preconception factors as well as those during fetal development,
- 2. infants from birth to 6 months of age, and
- 3. infants from 6 to 24 months of age.

Funds Avail Proposals for funding are eligible for up to \$2,000,000 total cost per project in funding.

The proposal should fit within a time frame of 36 to 48 months.

Deadline January 25, 2012 at 10am PST

CAREER DEVELOPMENT/TRAINING

Program/Link **PhRMA Foundation Research Starter Grants Program in Health Outcomes**

http://www.phrmafoundation.org/index.php?option=com_award&task=sdetail&id=16

Purpose The purpose of the PhRMA Foundation Research Starter Grants is to offer financial support to individuals beginning their independent research careers at the faculty level. This program supports individuals beginning independent research careers in academia who do not have other substantial sources of research funding. The Health Outcomes research programs spans a broad spectrum of issues from studies evaluating the effectiveness of a particular pharmaceutical intervention to the impact of reimbursement policies on the outcomes of care. It also ranges from the development and use of tools to perform patient-based assessments to analyses of the best way to disseminate the results of outcomes research to providers or consumers to encourage behavior change.

Funds Avail \$60,000 for one year

Deadline February 1, 2012

- Remarks**
- This program is not offered as a means to augment substantially funded research efforts. It is intended to offer support for researchers who are starting their independent research efforts.
 - Those holding the academic rank of instructor or assistant professor and investigators at the doctoral level with equivalent positions are eligible to apply for these research starter grants, providing their proposed research is neither directly nor indirectly subsidized to any significant degree by an extramural support mechanism.
 - The program is not intended for those in postdoctoral training programs. However, individuals in postdoctoral training scheduled to conclude and who will hold an academic appointment by January 1, 2012 may apply.
 - PhRMA is also accepting predoctoral, postdoctoral and sabbatical fellowship applications in health outcomes research at this same 2/1/12 deadline

Program/Link **Mentored Clinical & Translational Research Scholars ACTSI KL2 Program**

<http://www.actsi.org/areas/retcd/kl2/index.html>

Purpose Junior faculty members at the MD or PhD level from a wide variety of disciplines at Emory University, Morehouse School of Medicine, or Georgia Institute of Technology who are committed to an academic career in clinical and/or translational research and who have excellent potential to become an independent clinical investigator are encouraged to apply to the KL2 – Mentored Clinical and Translational Research Scholars (MCTRS) Program. The KL2 award provides support for didactic and mentored research training for junior faculty members committed to a career in clinical investigation.

Funds Avail For 75% salary support, a \$25,000/ year KL2 technical budget for research costs and tuition, and some salary support for the KL2 scholar’s Lead Mentor.

Deadline March 1, 2012

- Remarks**
- KL2 award recipients must devote 75% professional effort to the program (surgeons may devote 50% effort).
 - Partial or matching salary support from the applicant’s Division, Department or other non-federal sources is highly encouraged but not required.
 - Mentor required
 - The Masters of Science in Clinical Research (MSCR) is a component of the KL2 program, but please note that *applications for the MSCR can also be submitted independently from the KL2 applications*. See below for additional details on the [MSCR program](#).

Previous Emory Dept of Pediatrics KL2 awardees Drs. Andi Shane

(ashane@emory.edu) and Anne Fitzpatrick (anne.fitzpatrick@emory.edu) have invited those interested in this program to contact them to ask about the application and program requirements

Please contact stacy.heilman@emory.edu for pediatrics specific support and guidance, if you intend to apply for this KL2 opportunity

INTRAMURAL/SEED/PILOT

Program/Link **Emory+Children's Pediatric Research Center Pilot Program**

www.pedsresearch.org/news/article/2012-center-pilot-rfa

Purpose The primary goal is to build new collaborations that will lead to sustainable multi-investigator research programs, new grants, and important new discoveries related to our pediatric mission in producing innovative advances in child health research. See the RFA at the link above for specific focus topics for each of these pediatric centers:

- Children's Center for Cardiovascular Biology
- Children's Center for Clinical Outcomes Research & Public Health (CORPH)
- Children's Center for Cystic Fibrosis Research
- Children's Center for Developmental Lung Biology
- Children's Center for Immunology and Vaccines
- Children's Center for Pediatric Healthcare Technology Innovation
- Children's Center for Pediatric Nanomedicine
- Children's Center for Neuroscience
- Children's Center for Transplant Immunology and Immune Therapeutics

Funds Avail Up to \$50K for one year
(exception for Nanomedicine pilots that may budget up to \$60K)

Deadline March 1, 2012

Remarks

- Proposals that link researchers in different areas of expertise and/or at different institutions are particularly encouraged
- At least one principal investigator must be a faculty member in the Department of Pediatrics at Emory or on the staff of Children's Healthcare of Atlanta

Program/Link **Healthcare Innovation Program/ACTSI Seed Grant**

<http://hip.emory.edu/documents/hip%20seed%20grant.pdf>

Purpose The Emory/Georgia Tech Healthcare Innovation Program (HIP), in partnership with the Atlanta Clinical and Translational Science Institute (ACTSI), is pleased to invite research seed grant proposals in Healthcare Innovation. The seed grant program will fund multi-investigator, multi-disciplinary teams examining healthcare services and clinical effectiveness.

Awards will support innovative approaches that address issues of healthcare quality, costs, and/or access that are consistent with the goals of the HIP and the ACTSI (see: <http://www.hip.emory.edu/about/mission/index.html>).

Topics: Two types of studies will be considered; health services research and clinical effectiveness research.

Funds Avail Categories: Two categories of grants will be considered:
Preliminary Study Grants - \$25K for one year max
Complete Project Grants - \$25K/year for two years max

Deadline March 1, 2012

A letter of intent with the title of the project, the names of investigators, and the proposed total budget must be e-mailed no later than 2 weeks before submission to Maryam Carn, HIP Program Coordinator (maryam.carn@emory.edu).

Remarks

- Applications must include:
 - A minimum of two faculty investigators from different academic units (e.g., schools or departments) at Emory, Georgia Tech, and/or Morehouse School of Medicine
 - At least one medical or nursing staff member at Emory Healthcare, Children's, Grady, and/or the Atlanta VAMC. The hospital staff member may be represented by one of the university faculty.

Program/Link **The Emory University Research Committee (URC)**
<http://urc.emory.edu>

Purpose The University Research Committee (URC) is pleased to announce the call for proposals for the spring 2012 funding cycle of URC, ACTSI (Atlanta Clinical and Translational Science Institute) and a new category of funding priorities, high risk/high potential (HH) grants. This is the only award cycle for the 2011-12 academic year. Proposals are reviewed by one of the URC's five sub-committees: biological and health sciences, social sciences, natural sciences, humanities and the visual and performing arts.

Funds Avail \$30,000 for one year for URC and ACTSI
\$50,000 for High risk/High potential awards

Deadline Proposals must be submitted electronically to urcappl@emory.edu 6 pm, Friday, January 20, 2012

Remarks

- Applications are welcome from all regular, full-time Emory faculty.
- Please direct any questions or requests for additional information to Ling Guo, University Research Committee Coordinator, 2-7438 or lguo@emory.edu
- The new High risk/High potential category will focus on the quality of the ideas rather than the career stage of the investigator(s), therefore both senior and junior faculty may apply. Furthermore, the applicant is

strongly encouraged to consider the inter-disciplinary nature of the review team and to formulate the proposal for an educated, lay audience.

Program/Link **Emory Molecular and Translational Imaging Research Center (EMTIC)**
http://www.actsi.org/news/2011/documents/p50_2011.pdf?utm_source=er&utm_medium=email&utm_campaign=eRoundup_120911

Purpose Opportunity for both trainees and established scientists to acquire preliminary data in the quantitative molecular imaging arena on which to base competitive future R01 proposals. Imaging modalities of interest include CT, MR, Optical, PET, SPECT and US. Pilots must have the potential to be translated to clinical applications with a benefit to cancer patients.

Funds Avail \$20,000 for one year

Deadline March 15, 2012

Remarks

- Applicants must be Emory Faculty at the level of Instructor or above.
- Contact Jessica Paulishen jpauli2@emory.edu with questions and for application information

Program/Link **Alex's Lemonade Stand Foundation Bridge Grants**
<http://www.alexslimonade.org/grants/bridge-grants>

Purpose ALSF's Bridge Grants are intended to keep scientist's projects on track while they plan and apply to new funding sources to ensure novel childhood cancer research projects are not compromised.

Funds Avail \$100,000 for 12 months. Funds to be used for supplies, personnel or the PI's salary

Deadline Applications currently being accepted and will be reviewed and funded on a rolling basis. Applications will no longer be accepted once three have been funded or the deadline of January 9, 2012 is reached

Remarks

- Applicants must have applied for NIH funding in the last six months and were scored competitively, but outside the funding range
- Applicants must have a plan to reapply for NIH funding in the near future
- Projects must align with the mission of ALSF and be focused on better diagnosis of or cures for childhood cancers.
- Projects focused on complications from cancer treatments and quality of life and care will not be considered.

Research Related Educational Opportunity Announcements

Master of Science in Clinical Research (MSCR) degree program

http://www.actsi.org/areas/retcd/mscr1/mscr_emory/application_instructions.html

The MSCR provides didactic and mentored clinical and/or translational research training and is designed for participants who hold a doctorate or equivalent degree (such as physicians

including fellows and junior faculty and PhD-level scientists including postdoctoral fellows and junior faculty) and have demonstrated a commitment to a career in clinical investigation that incorporates clinical and/or translational research. Applications are now being accepted for classes beginning in August 2012. A limited number of tuition scholarships are available for the program from the Research Education, Training, and Career Development (RETCD) program of the Atlanta Clinical and Translational Science Institute (ACTSI, NIH-funded CTSA award). While there is a rolling admissions policy for the MSCR program, applicants are encouraged to apply soon in order to also apply for available scholarship funds.

Additional information can be found at the ACTSI website (www.actsi.org/retcd) and by contacting Cheryl Sroka, RETCD Program Administrator (csroka@emory.edu ; 404-727-5096).

Biostatistics Course

The ACTSI Certificate Program in Translational Research is offering a basic biostatistics course and invites junior faculty members to enroll. This is a spring semester course which meets every Tuesday from 1:00-2:50 p.m. beginning on January 24 until May 1, 2012. Contact Cheryl Sroka at csroka@emory.edu for more information on how to apply.

Certificate Program in Translational Research

As part of the Howard Hughes Medical Institute “Med into Grad” Initiative, the Emory Laney Graduate School is now offering a Certificate Program in Translational Research. Applicants must be PhD graduate students in the biomedical sciences and/or biomedical engineering at Emory, Morehouse School of Medicine, and Georgia Tech and with an interest in obtaining training in translational research. Applications are currently being accepted for Fall 2012. See the link below for additional information.

http://www.actsi.org/news/2011/documents/cert_retcd.pdf?utm_source=er&utm_medium=email&utm_campaign=eRoundup_121611

NIH STANDARD DUE DATES CITED ABOVE

Mechanism(s)	Cycle I Due Date	Cycle II Due Date	Cycle III Due Date
P Series ALL – new, renewal, resubmission, revision	25-Jan	25-May	25-Sept
R01 NEW <i>renewal, resubmission, revision</i>	5-Feb <i>5-Mar</i>	5-Jun <i>5-Jul</i>	5-Oct <i>5-Nov</i>
R41, R42, R43, R44, U43, U44, <i>All - new, renewal, resubmission, revision</i>	5-April	5-Aug	5-Dec
R03, R21, R34	16-Feb	16-Jun	16-Oct

NEW <i>renewal, resubmission, revision</i>	<i>16-Mar</i>	<i>16-Jul</i>	<i>16-Nov</i>
K series NEW <i>renewal, resubmission, revision</i>	12-Feb <i>12-Mar</i>	12-Jun <i>12-Jul</i>	12-Oct <i>12-Nov</i>
All AIDS and AIDS-Related Applications (for mechanisms cited above) <i>All - new, renewal, resubmission, revision</i>	7-May	7-Sept	7-Jan

For the full schedule of NIH standard due dates, see
<http://grants1.nih.gov/grants/funding/submissionschedule.htm>



ABOUT THE BIRD:

This compilation of general interest funding opportunities and announcements with possible collaborative potential is distributed to our pediatric research community monthly. It is compiled by the Emory-Children's Pediatric Research Center to disseminate funding announcements of potential interest in a consolidated manner. More specific announcements are distributed in a more targeted fashion.

If you are not receiving this directly from Stacy Heilman and wish to be added to our Pediatric Research listserv, please e-mail stacy.heilman@emory.edu to make the request. Please also contact Stacy if you are interested in applying for any pediatric focused research funding opportunities and/or if you are interested in building collaborative efforts and programs towards applying for future pediatric research funding.